Foot growth disorder after surgery of lower limb malignant bone tumor in a pediatric series.

Orthop Traumatol Surg Res

Service d'orthopédie pédiatrique, Hôpital Necker Enfants-Malades, AP-HP, 149 rue de Sèvres, 75015 Paris, France; Service d'orthopédie pédiatrique, CHU de Caen, av. de la côte de nacre, 14000 Caen, France. Electronic address:

Published: December 2024

Bakground: Child malignant bone tumors often develop near growth cartilage. The gold standard surgery consists in large segmental resection. This resection often requires the sacrifice of growth cartilage, leading to inequality of limb length. Prothesis are used for reconstruction when the epiphysis is resected, otherwise different strategies of osteosyntheses and grafts may be an option.

Hypothesis: The aim of the study was to analyze the foot size inequality after surgery of lower limb malignant bone tumor in patients with growth residual.

Patients And Methods: A retrospective study analyzed the data of 60 patients followed in an oncology pediatric center, between January 2008 and December 2018, for surgically treated malignant bone tumor. All surgeries were realized between January 1992 and December 2013. The primary outcome was the foot size inequality at the last consultation. Categorical variables were described by frequencies and percentages, and compared with Student tests. Continuous variables were described by median and interquartile range, the linear relationship between the foot size inequality and the explanatory variables were analyzed with Pearson tests.

Results: A foot size inequality of 1.15 cm [-0.5 - 3] was measured, a statistically significant difference (p < 0.0001). Younger children had a greater difference, as the patients with a greater final leg inequality. The children who required several surgeries because of mechanical issues also had a higher foot length difference.

Discussion: The foot length inequality after bone tumor surgery of the lower limb in children with residual growth potential is a reality not enough described LEVEL OF EVIDENCE: IV.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.otsr.2024.104150DOI Listing

Publication Analysis

Top Keywords

malignant bone
16
foot size
16
size inequality
16
bone tumor
12
surgery lower
8
lower limb
8
limb malignant
8
growth cartilage
8
variables described
8
foot
5

Similar Publications

Depletion of myeloid-derived suppressor cells sensitizes murine multiple myeloma to PD-1 checkpoint inhibitors.

J Immunother Cancer

January 2025

Center for Translational Research in Hematologic Malignancies, Houston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, Texas, USA

Background: Cancer immunotherapy using immune checkpoint blockade (ICB) has revolutionized cancer treatment. However, patients with multiple myeloma (MM) rarely respond to ICB. Accumulating evidence indicates that the complicated tumor microenvironment (TME) significantly impacts the efficacy of ICB therapy.

View Article and Find Full Text PDF

Metabolic reprogramming, malignant transformation and metastasis: lessons from chronic lymphocytic leukaemia and prostate cancer.

Cancer Lett

January 2025

Clinical and Health Sciences, University of South Australia, Adelaide, Australia; Department of Histopathology, Trinity College Dublin, St. James's Hospital, Dublin, Ireland. Electronic address:

Metabolic reprogramming is a hallmark of cancer, crucial for malignant transformation and metastasis. Chronic lymphocytic leukaemia (CLL) and prostate cancer exhibit similar metabolic adaptations, particularly in glucose and lipid metabolism. Understanding this metabolic plasticity is crucial for identifying mechanisms contributing to metastasis.

View Article and Find Full Text PDF

Background: Post-transplant cyclophosphamide (PTCy) is a commonly used graft-vs-host disease (GVHD) prophylaxis, particularly in the setting of haploidentical (haplo) hematopoietic cell transplantation (HCT). The rate of graft failure has been reported to be as high as 12-20% in haplo-HCT recipients using PTCy. The objective of this study was to determine if donor type influenced the risk of late graft failure following RIC HCT using PTCy-based GVHD prophylaxis.

View Article and Find Full Text PDF

A non-metallic PEEK topology optimization reconstruction implant for large mandibular continuity defects, validated using the MANDYBILATOR apparatus.

Sci Rep

January 2025

Department of Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Hanzeplein 1, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands.

In cases of large mandibular continuity defects resulting from malignancy resection, the current standard of care involves using patient-specific/custom titanium reconstruction plates along with autogenous grafts (fibula, scapula, or iliac crest segments). However, when grafts are not feasible or desired, only the reconstruction plate is used to bridge the gap. Unfortunately, metal osteosynthesis and reconstruction plates, including titanium, exhibit adverse effects such as stress-shielding and limitations in accurate postoperative irradiation (especially with proton-beam therapy).

View Article and Find Full Text PDF

Twenty years of experience with lesions involving the temporomandibular joint and adjacent structures complex.

Int J Oral Maxillofac Surg

January 2025

Department of Oral Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Key Laboratory of Stomatology and Shanghai Research Institute of Stomatology, Shanghai, China; National Clinical Research Center of Stomatology, Shanghai, China. Electronic address:

With their close anatomical relationship, the temporomandibular joint (TMJ), mandibular ramus, skull base, ear, and infratemporal fossa make up a complex structure that may collectively be referred to as the 'TMJ and adjacent structures complex' (TASC). This study presents the neoplasms that may be encountered in the TASC region and their classification, which may be useful for the surgical treatment. Data of 1022 consecutive patients treated with resection of TASC neoplasms from May 2000 to October 2022 were reviewed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!